{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-004891","form_type":"8-K","ticker":"DMAC","cik":"0001401040","company_name":"DiaMedica Therapeutics Inc.","filed_at":"2025-02-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.524801+00:00","generated_at":"2026-05-26T05:41:23.827910+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"DiaMedica Therapeutics appoints Daniel J. O'Connor to Board of Directors","bullets":["Daniel J. O'Connor appointed to Board effective Feb 20, 2025; joins Audit and Nominating & Corporate Governance Committees.","O'Connor previously served as CEO of Ambrx Biopharma, guiding it from $40M valuation to $2B acquisition by Johnson & Johnson in 14 months.","He received option to purchase 64,242 common shares at fair market value, vesting quarterly over three years.","Initial equity award for non-employee directors increased from 0.12% to 0.15% of outstanding common shares.","Non-employee director annual equity award also increased from 0.06% to 0.075% of outstanding common shares."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-004891","json":"https://secwatch.observer/filing/0001437749-25-004891.json","markdown":"https://secwatch.observer/filing/0001437749-25-004891.md","text":"https://secwatch.observer/filing/0001437749-25-004891.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1401040/000143774925004891/0001437749-25-004891-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1401040/000143774925004891/dmtp20250221_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T05:41:23.827910+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4557800d06","claim":"Daniel J. O'Connor was appointed as Director at DiaMedica Therapeutics Inc..","evidence_excerpt":"On February 20, 2025, the Board of Directors (the “Board”) of DiaMedica Therapeutics Inc. (the “Company”), upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Daniel J. O’Connor to the Board, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1401040/000143774925004891/0001437749-25-004891-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}